Why the study?
Does short-term hypoxia prevent Angiotensin II-induced cardiomyocyte apoptosis?
Does short-term hypoxia prevent Angiotensin II-induced cardiomyocyte apoptosis?
Short-term hypoxia protects cardiomyocytes from Angiotensin II-stimulated apoptosis by upregulating the Mas receptor and inhibiting AT1R signaling, suggesting a potential therapeutic pathway for hypertensive heart disease.
Short-term hypoxia may attenuate Ang II-induced apoptosis in animal cardiomyocytes; leaves open translation to human hypertensive heart disease.
Hypertension‐stimulated cardiac hypertrophy and apoptosis play critical roles in the progression of heart failure. Our previous study suggested that hypertensive angiotensin II (Ang II) enhanced insulin‐like growth factor receptor II (IGF‐IIR) expression and cardiomyocyte apoptosis, which are involved JNK activation, sirtuin1 (SIRT1) degradation, and heat‐shock transcription factor 1 (HSF1) acetylation. Moreover, previous studies have implied that short‐term hypoxia (STH) might exert cardioprotective effects. However, the effects of STH on Ang II‐induced cardiomyocyte apoptosis remain unknown. In this study, we found that STH reduced myocardial apoptosis caused by Ang II via upregulation of the Mas receptor (MasR) to inhibit the AT 1 R signaling pathway. STH activates MasR to counteract the Ang II pro‐apoptotic signaling cascade by inhibiting IGF‐IIR expression via downregulation of JNK activation and reduction of SIRT1 degradation. Hence, HSF could remain deacetylated, and repress IGF‐IIR expression. These effects decrease the activation of downstream pro‐apoptotic and hypertrophic cascades and protect cardiomyocytes from Ang II‐induced injury. In addition, we also found that silencing MasR expression enhanced Ang II‐induced cardiac hypertrophy and the apoptosis signaling pathway. These findings suggest a critical role for MasR in cardiomyocyte survival. Altogether, our findings indicate that STH protects cardiomyocytes from Ang II‐stimulated apoptosis. The protective effects of STH are associated with the upregulation of MasR to inhibit AT 1 R signaling. STH could be a potential therapeutic strategy for cardiac diseases in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: